Vical’s Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipients

22nd January 2018 Uncategorised 0

After the cytomegalovirus vaccine Astellas licensed from Vical failed in a kidney transplant phase 2 study, hope of the shot rested on a phase 3 in hematopoietic stem cell transplant recipients. But that hope has just been shattered too.

More: Vical’s Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipients
Source: fierce